TY - JOUR
T1 - Case-oriented pathways analysis in pancreatic adenocarcinoma using data from a sleeping beauty transposon mutagenesis screen
AU - Ho, Yen Yi
AU - Starr, Tim
AU - LaRue, Rebecca S
AU - Largaespada, David A
N1 - Publisher Copyright:
© 2016 Ho et al.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Background: Mutation studies of pancreatic ductal adenocarcinoma (PDA) have revealed complicated heterogeneous genomic landscapes of the disease. These studies cataloged a number of genes mutated at high frequencies, but also report a very large number of genes mutated in lower percentages of tumors. Taking advantage of a well-established forward genetic screening technique, with the Sleeping Beauty (SB) transposon, several studies produced PDA and discovered a number of common insertion sites (CIS) and associated genes that are recurrently mutated at high frequencies. As with human mutation studies, a very large number of genes were found to be altered by transposon insertion at low frequencies. These low frequency CIS associated genes may be very valuable to consider for their roles in cancer, since collectively they might emerge from a core group of genetic pathways. Result: In this paper, we determined whether the genetic mutations in SB-accelerated PDA occur within a collated group of biological processes defined as gene sets. The approach considered both genes mutated in high and lower frequencies. We implemented a case-oriented, gene set enrichment analysis (CO-GSEA) on SB altered genes in PDA. Compared to traditional GSEA, CO-GSEA enables us to consider individual characteristics of mutation profiles of each PDA tumor. We identified genetic pathways with higher numbers of genetic mutations than expected by chance. We also present the correlations between these significant enriched genetic pathways, and their associations with CIS genes. Conclusion: These data suggest that certain pathway alterations cooperate in PDA development.
AB - Background: Mutation studies of pancreatic ductal adenocarcinoma (PDA) have revealed complicated heterogeneous genomic landscapes of the disease. These studies cataloged a number of genes mutated at high frequencies, but also report a very large number of genes mutated in lower percentages of tumors. Taking advantage of a well-established forward genetic screening technique, with the Sleeping Beauty (SB) transposon, several studies produced PDA and discovered a number of common insertion sites (CIS) and associated genes that are recurrently mutated at high frequencies. As with human mutation studies, a very large number of genes were found to be altered by transposon insertion at low frequencies. These low frequency CIS associated genes may be very valuable to consider for their roles in cancer, since collectively they might emerge from a core group of genetic pathways. Result: In this paper, we determined whether the genetic mutations in SB-accelerated PDA occur within a collated group of biological processes defined as gene sets. The approach considered both genes mutated in high and lower frequencies. We implemented a case-oriented, gene set enrichment analysis (CO-GSEA) on SB altered genes in PDA. Compared to traditional GSEA, CO-GSEA enables us to consider individual characteristics of mutation profiles of each PDA tumor. We identified genetic pathways with higher numbers of genetic mutations than expected by chance. We also present the correlations between these significant enriched genetic pathways, and their associations with CIS genes. Conclusion: These data suggest that certain pathway alterations cooperate in PDA development.
KW - CIS
KW - Case-oriented gene set analysis
KW - Common insertion sites
KW - Forward genetic screen
KW - Pathways correlations
KW - Sleeping Beauty transposon
UR - http://www.scopus.com/inward/record.url?scp=84962919791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962919791&partnerID=8YFLogxK
U2 - 10.1186/s12920-016-0176-7
DO - 10.1186/s12920-016-0176-7
M3 - Article
C2 - 27038937
AN - SCOPUS:84962919791
SN - 1755-8794
VL - 9
JO - BMC Medical Genomics
JF - BMC Medical Genomics
IS - 1
M1 - 16
ER -